Tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK) are clinically overlapping disorders characterized by childhood-onset muscle weakness and a variable occurrence of multisystemic signs, including short stature, thrombocytopenia, and hyposplenism. TAM/STRMK is caused by gain-of-function mutations in the Ca 2+ sensor STIM1 or the Ca 2+ channel ORAI1, both of which regulate Ca 2+ homeostasis through the ubiquitous store-operated Ca 2+ entry (SOCE) mechanism. Functional experiments in cells have demonstrated that the TAM/STRMK mutations induce SOCE overactivation, resulting in excessive influx of extracellular Ca 2+ . There is currently no treatment for TAM/STRMK, but SOCE is amenable to manipulation. Here, we crossed
Stim1
R304W/+ mice harboring the most common TAM/STRMK mutation with
Orai1
R93W/+ mice carrying an ORAI1 mutation partially obstructing Ca 2+ influx. Compared with
Stim1
R304W/+ littermates,
Stim1
R304W/+
Orai1
R93W/+ offspring showed a normalization of bone architecture, spleen histology, and muscle morphology; an increase of thrombocytes; and improved muscle contraction and relaxation kinetics. Accordingly, comparative RNA-Seq detected more than 1,200 dysregulated genes in
Stim1
R304W/+ muscle and revealed a major restoration of gene expression in
Stim1
R304W/+
Orai1
R93W/+ mice. Altogether, we provide physiological, morphological, functional, and molecular data highlighting the therapeutic potential of ORAI1 inhibition to rescue the multisystemic TAM/STRMK signs, and we identified myostatin as a promising biomarker for TAM/STRMK in humans and mice.
Tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK) form a clinical continuum associating progressive muscle weakness with additional multi-systemic anomalies of the bones, skin, spleen, and platelets. TAM/STRMK arises from excessive extracellular Ca2+ entry due to gain-of-function mutations in the Ca2+ sensor STIM1 or the Ca2+ channel ORAI1. Currently, no treatment is available. Here we assessed the therapeutic potential of ORAI1 downregulation to anticipate and reverse disease development in a faithful mouse model carrying the most common TAM/STRMK mutation and recapitulating the main signs of the human disorder. To this aim, we crossed Stim1R304W/+ mice with Orai1+/− mice expressing 50% of ORAI1. Systematic phenotyping of the offspring revealed that the Stim1R304W/+Orai1+/− mice were born with a normalized ratio and showed improved postnatal growth, bone architecture, and partly ameliorated muscle function and structure compared with their Stim1R304W/+ littermates. We also produced AAV particles containing Orai1-specific shRNAs, and intramuscular injections of Stim1R304W/+ mice improved the skeletal muscle contraction and relaxation properties, while muscle histology remained unchanged. Altogether, we provide the proof-of-concept that Orai1 silencing partially prevents the development of the multi-systemic TAM/STRMK phenotype in mice, and we also established an approach to target Orai1 expression in postnatal tissues.
Store-operated Ca2+ entry (SOCE) controls Ca2+ homeostasis and mediates multiple Ca2+-dependent signaling pathways and cellular processes. It relies on the concerted activity of the reticular Ca2+ sensor STIM1 and the plasma membrane Ca2+ channel ORAI1. STIM1 and ORAI1 gain-of-function (GoF) mutations induce SOCE overactivity and excessive Ca2+ influx, leading to tubular aggregate myopathy (TAM) and Stormorken syndrome (STRMK), two overlapping disorders characterized by muscle weakness and a variable occurrence of multi-systemic anomalies affecting spleen, skin, and platelets. To date, different STIM1 mouse models exist, but only a single ORAI1 mouse model with muscle-specific TAM/STRMK phenotype has been described, precluding a comparative analysis of the physiopathology in all affected tissues. Here, we generated and characterized mice harboring a prevalent ORAI1 TAM/STRMK mutation and we provide phenotypic, physiological, biochemical, and functional data. Examination of Orai1V109M/+ mice revealed smaller size, spleen enlargement, reduced muscle force, and decreased platelet numbers. Morphological analyses of muscle sections evidenced the presence of tubular aggregates, the histopathological hallmark on biopsies from TAM/STRMK patients absent in all reported STIM1 models. Overall, Orai1V109M/+ mice reliably recapitulate the human disorder and highlight the primary physiological defects caused by ORAI1 gain-of-function mutations. They also provide the possibility to investigate the formation of tubular aggregates and to develop a common therapy for different TAM/STRMK forms.
Physiopathologie et approches thérapeutiques de la myopathie à agrégats tubulaires (TAM) et du syndrome de Stormorken (STRMK): La myopathie à agrégats tubulaires (TAM) et le syndrome de Stormorken (STRMK) forment un spectre clinique affectant le muscle squelettique, la rate et les plaquettes. TAM/STRMK est causée par des mutations à gain de fonction dans STIM1 et ORAI1, entraînant une entrée excessive de Ca²⁺. Le mécanisme pathologique de TAM/STRMK reste mal compris, et aucun traitement n’est disponible. Pour y remédier, j’ai généré et caractérisé le modèle murin Orai1V109M/+, qui a reproduit les signes cliniques de la maladie. J’ai également évalué des stratégies thérapeutiques ciblant ORAI1 avec des shRNA et des ASOs, améliorant partiellement les phénotypes du muscle et de la rate dans le modèle murin Stim1R304W/+. Enfin, j’ai étudié le rôle de STIM1 dans le vieillissement physiologique. Sa réduction a induit une fatigue musculaire due à des altérations mitochondriales. Ces résultats éclaircissent le rôle du Ca2+ dans la physiologie et dans TAM/STRMK, et identifient la modulation d’ORAI1 comme une approche thérapeutique prometteuse.